ADMA BIOLOGICS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
ADMA$12.73-3.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023
CONDENSED CONSOLIDATEDBALANCE SHEETS
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| (In thousands, except share data) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $45,325 | $51,352 |
| Accounts receivable, net | 49,621 | 27,421 |
| Inventories | 177,732 | 172,906 |
| Prepaid expenses and other current assets | 3,741 | 5,334 |
| Total current assets | 276,419 | 257,013 |
| Property and equipment, net | 55,317 | 53,835 |
| Intangible assets, net | 321 | 499 |
| Goodwill | 3,530 | 3,530 |
| Right-to-use assets | 9,397 | 9,635 |
| Deposits and other assets | 5,891 | 4,670 |
| TOTAL ASSETS | $350,875 | $329,182 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $17,186 | $15,660 |
| Accrued expenses and other current liabilities | 33,691 | 32,919 |
| Current portion of deferred revenue | 1,118 | 182 |
| Current portion of lease obligations | 1,093 | 1,045 |
| Total current liabilities | 53,088 | 49,806 |
| Senior notes payable, net of discount | 130,847 | 130,594 |
| Deferred revenue, net of current portion | 1,654 | 1,690 |
| End of term fee | 1,688 | 1,688 |
| Lease obligations, net of current portion | 9,487 | 9,779 |
| Other non-current liabilities | 405 | 419 |
| TOTAL LIABILITIES | 197,169 | 193,976 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding | - | - |
| Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 231,769,765 and 226,063,032 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 23 | 23 |
| Additional paid-in capital | 642,133 | 641,439 |
| Accumulated deficit | (488,450) | (506,256) |
| TOTAL STOCKHOLDERS’ EQUITY | 153,706 | 135,206 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $350,875 | $329,182 |
Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.